May Health Raises $25 Million in Series B Funding to Advance Development for Ovarian Rebalancing Therapy
– Bpifrance and Trill Impact Ventures co-led the round, joining founding investor Sofinnova Partners, to support the company’s pivotal REBALANCE study evaluating Ovarian Rebalancing in women with infertility caused by PCOS
PARIS, May 13, 2024–May Health, a clinical-stage medical device company dedicated to helping those living with the endocrine disorder polycystic ovary syndrome (PCOS), today announced it has closed a $25 million Series B financing round, co-led by Bpifrance and Trill Impact with participation from founding investor Sofinnova Partners, as well as Avestria Ventures and Kidron Capital Assets LP. Funds will be used to support the company’s growth and advance its Ovarian Rebalancing™ therapy through the pivotal REBALANCE Study, evaluating its potential to address PCOS-related infertility.
